论文部分内容阅读
常见呼吸道病原菌对抗生素耐药性的快速增长向公共卫生事业提出了一个非常现实的挑战。为此 ,目前急需一类既可覆盖所有常见呼吸道病原菌、包括耐青霉素和大环内酯类抗生素肺炎链球菌等耐药菌株、又能抵抗耐药性发展的新颖抗生素。telithromycin作为第一个获得广泛临床评价的新颖类抗生素 酮内酯类抗生素药物 ,其正是专门设计达到上述目标的 :对该类药物进行了数种创新性结构修饰 ,使其不仅对各种常见呼吸道病原菌有效 ,而且还使它的耐药性风险降至最低 ,故telithromycin将成为当今社区获得性呼吸道感染经验疗法中的一种重要的新的临床选择 ,尤在耐大环内酯类的抗生素肺炎链球菌感染及其流行地区最具价值
Common respiratory pathogens The rapid growth of antibiotic resistance poses a very real challenge to public health. For this reason, there is an urgent need for a class of novel antibiotics that can cover all common respiratory pathogens, including resistant strains such as penicillin and macrolide antibiotics Streptococcus pneumoniae, and resistance to drug resistance. Telithromycin, the first novel class of antibiotic ketolide antibiotics that has received a wide range of clinical evaluations, has been specifically designed to achieve these goals: Several innovative structural modifications have been made to these drugs not only for a variety of common Respiratory pathogens are effective and also minimize the risk of their resistance so that telithromycin will be an important new clinical option in the empirical therapy of community-acquired respiratory infections today, especially in the case of macrolide-resistant antibiotics Streptococcus pneumoniae infection and its most popular areas of value